ABSTRACT
Background Identification of risk factors for COVID-19-associated hospitalization is needed to guide prevention and clinical care.
Objective To examine if age, sex, race/ethnicity, and underlying medical conditions is independently associated with COVID-19-associated hospitalizations.
Design Cross-sectional.
Setting 70 counties within 12 states participating in the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET) and a population-based sample of non-hospitalized adults residing in the COVID-NET catchment area from the Behavioral Risk Factor Surveillance System.
Participants U.S. community-dwelling adults (≥18 years) with laboratory-confirmed COVID-19-associated hospitalizations, March 1- June 23, 2020.
Measurements Adjusted rate ratios (aRR) of hospitalization by age, sex, race/ethnicity and underlying medical conditions (hypertension, coronary artery disease, history of stroke, diabetes, obesity [BMI ≥30 kg/m2], severe obesity [BMI≥40 kg/m2], chronic kidney disease, asthma, and chronic obstructive pulmonary disease).
Results Our sample included 5,416 adults with COVID-19-associated hospitalizations. Adults with (versus without) severe obesity (aRR:4.4; 95%CI: 3.4, 5.7), chronic kidney disease (aRR:4.0; 95%CI: 3.0, 5.2), diabetes (aRR:3.2; 95%CI: 2.5, 4.1), obesity (aRR:2.9; 95%CI: 2.3, 3.5), hypertension (aRR:2.8; 95%CI: 2.3, 3.4), and asthma (aRR:1.4; 95%CI: 1.1, 1.7) had higher rates of hospitalization, after adjusting for age, sex, and race/ethnicity. In models adjusting for the presence of an individual underlying medical condition, higher hospitalization rates were observed for adults ≥65 years, 45-64 years (versus 18-44 years), males (versus females), and non-Hispanic black and other race/ethnicities (versus non-Hispanic whites).
Limitations Interim analysis limited to hospitalizations with underlying medical condition data.
Conclusion Our findings elucidate groups with higher hospitalization risk that may benefit from targeted preventive and therapeutic interventions.
Competing Interest Statement
Dr. Anderson reports personal fees from AbbVie, personal fees from Pfizer, grants from Pfizer, grants from Merck, grants from Micron, grants from Paxvax, grants from Sanofi Pasteur, grants from Novavax, grants from MedImmune, grants from Regeneron, grants from GSK, outside the submitted work. Mr. Henderson, Ms. Kim, Ms. George, and Ms. Hill report grants from Council of State and Territorial Epidemiologists (CSTE), during the conduct of the study. Dr. Lynfield reports grants from CDC- Emerging Infections Program, during the conduct of the study; and Royalties from a book on infectious disease surveillance and compensation for AAP Red Book (Report from Committee on Infectious Disease) donated to Minnesota Dept of Health. Dr. Schaffner reports grants from CDC, during the conduct of the study; personal fees from VBI Vaccines, outside the submitted work. Dr. Talbot reports other from Seqirus, outside the submitted work.
Funding Statement
This work was supported by the Centers of Disease Control and Prevention through an Emerging Infections Program cooperative agreement (grant CK17-1701) and through a Council of State and Territorial Epidemiologists cooperative agreement (grant NU38OT000297-02-00).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis was exempt from CDC's Institutional Review Board, as it was considered part of public health surveillance and emergency response. Participating sites obtained approval for the COVID-NET surveillance protocol from their respective state and local IRBs, as required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
For the COVID-NET Investigation Group:
Michael Whitaker (CDC COVID-NET, Eagle Global Scientific, Atlanta, GA, USA); Alissa O’Halloran (CDC COVID-NET); Rachel Holstein (CDC COVID-NET, Oak Ridge Institute for Science and Education); William Garvin (CDC Division of Population Health); Shua J. Chai (California Emerging Infections Program, Oakland, CA, Career Epidemiology Field Officer, CDC/CPR/DSLR); Breanna Kawasaki (Colorado Department of Public Health and Environment, Denver, CO); James Meek (Connecticut Emerging Infections Program, Yale School of Public Health, New Haven CT); Kyle P. Openo (Emerging Infections Program, Georgia Department of Health, Atlanta, GA, Veterans Affairs Medical Center, Atlanta, GA, Foundation for Atlanta Veterans Education and Research, Decatur, GA); Maya L. Monroe (Maryland Department of Health, Baltimore, MD); Justin Henderson (Michigan Department of Health and Human Services, Lansing, MI); Kathy Como-Sabetti (Minnesota Department of Health, St. Paul, MN); Sarah Shrum Davis (New Mexico Department of Health, Santa Fe, NM); Nancy L. Spina (New York State Department of Health, Albany, NY); Christina B. Felsen (University of Rochester School of Medicine and Dentistry, Rochester, NY); Nicole West (Oregon Health Authority, Portland, OR); William Schaffner (Vanderbilt University School of Medicine, Nashville, TN); Andrea George (Salt Lake County Health Department, Salt Lake City, UT)
Data Availability
Data is not publically available at this time.
